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Dear Editor,
Circulatory assist devices require
tight anticoagulation therapy and may
be complicated by severe bleeding.
Despite warnings related to potential
lethal thrombotic complications, off-
label use of recombinant factor VIIa
(rFVIIa) is increasingly reported for
refractory hemorrhage, including
after cardiac surgery [1, 2]. However,
its use in patients with circulatory
assist devices has seldom been
reported and its safety remains to
be established [3–5].
We reviewed 12 consecutive
patients with surgically implanted
devices who received rFVIIa as
rescue treatment for intractable life-
threatening bleeding between March
2004 and November 2009 (Table 1).
According to strict and constringent
local consensus guidelines, a sys-
tematic cross-check for aggressive
correction of hypothermia, acidosis,
and coagulation factors with parallel
surgical control for bleeding or
embolization was obtained before
rFVIIa administration in all cases.
The median age of patients
was 45 years. The rFVIIa was
administered in the operating room
(3/12), in the intensive care unit
(7/12), or both (2/12). Underlying
conditions were cardiovascular
surgery (11/12, including 4 heart
transplantations) and bipulmonary
transplantation (1/12). The device
was an extracorporal membrane
oxygenator (9/12) and a left ventric-
ular assist device (3/12). Median dose
of rFVIIa was 95 lg/kg (45–180),
administered in one (3/12) or several
doses (9/12).
In these otherwise terminal
patients, the bleeding assessed by the
number of ml/kg of packed red blood
cells and fresh frozen plasma
requirement within 12 h before and
after rFVIIa administration was sig-
nificantly reduced. Six patients (50%)
died within 30 days, including 2
(18%) from persistent bleeding. A
careful analysis of coagulation and
other physiological parameters did
not reveal significant difference
between responders and
non-responders.
Table 1 Patient characteristics
Age
(years)
Type
of device
Total dose
of rFVIIa
(lg/kg)
Number
of doses
Thrombo-
embolic
event
Device
clotting
PRBC requirements
(ml/kg)
FFP requirements
(ml/kg)
Outcome at
30 days
12 h
before
12 h
after
D
(%)
12 h
before
12 h
after
D
(%)
1 10 ECMO 180 2 No No 96.0 75.0 -22 26.8 35.7 33 Alive
2 \1 ECMO 180 2 No No 270.0 77.0 -71 160 42 -74 Death day 7 from
multiple organ
failure
3 15 ECMO 45 1 No No 22.8 35.9 57 10.9 21.7 99 Alive
4 \1 ECMO 180 2 Stroke No 130.0 37.0 -72 111 107 -4 Death day 2 from
hemorrhage
5 55 ECMO 105 1 No No 182.6 6.5 -96 76.1 21.7 -71 Alive
6 51 ECMO 90 3 No No 66.3 34.9 -47 52.3 34.9 -33 Death day 9 from
cardiogenic
shock
7 43 LVAD 100 2 No No 105.0 40.0 -62 75 20.8 -72 Alive
8 47 ECMO 54 1 No No 31.4 45.3 44 34.9 49.4 42 Death day 1 from
hemorrhage
9 49 LVAD 60 2 No No 33.8 11.3 -67 25 6.3 -75 Alive
10 63 LVAD 76 3 No No 34.7 6.3 -82 34.2 5.3 -85 Death day 18 from
septic shock
11 46 ECMO 126 2 No No 88.4 18.9 -79 63.2 26.3 -58 Death day 7 from
septic shock
12 25 ECMO 47 2 No No 144.0 56.0 -61 100 43.3 -57 Alive
ECMO extracorporal membrane oxygenator; LVAD Thoratec IVAD as left ventricular assist device; PRBC packed red blood cells (300
ml per unit), D p = 0.007 by Wilcoxon T test; FFP fresh frozen plasma (250 ml per unit), D p = 0.007 by Wilcoxon T test
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In all cases, adequate anticoagula-
tion was further maintained and no
circuit thrombosis occurred; hence no
device required replacement. One
thromboembolic complication occur-
red (a stroke) in a neonate following
cardiac arrest after a Jatene switch.
The relationship between this event
and the rFVIIa administration
remained unclear.
We conclude that after meticulous
control for all other potential con-
tributing factors, the careful use of
small and if necessary repeated doses
of rFVIIa (25–30 lg/kg), allowed one
to control life-threatening intractable
bleeding in 9/12 patients with surgi-
cally implanted circulatory assistance
devices without any clot of the
devices. As suggested by current
guidelines, these data confirm pre-
liminary reports [3–5], but the safety
of rFVIIa in this context should now
be confirmed by controlled trials in
larger groups of patients.
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